Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HPV vaccines: Global perspectives.

Gaurav Gupta1, Reinhard Glueck1, Pankaj R Patel1

  • 1a Vaccine Technology Centre, Zydus Biologics Compound , Changodar, Ahmedabad , Gujarat , India.

Human Vaccines & Immunotherapeutics
|April 1, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics.

Drug development research·2021
Same author

Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.

Heliyon·2021
Same author

A 2-fold Approach to Polyoma Virus (BK) Nephropathy in Kidney Transplants: Distinguishing Direct Virus Effects From Cognate T Cell-mediated Inflammation.

Transplantation·2021
Same author

Goniotomy for initial and re-surgery for childhood glaucoma in Northern India.

Indian journal of ophthalmology·2021
Same author

Analysis of the parental satisfaction for retinopathy of prematurity screening using binocular indirect ophthalmoscopy versus wide field retinal imaging.

Indian journal of ophthalmology·2021
Same author

Effects of curcumin-loaded poly(lactic-co-glycolic acid) nanoparticles in MDA-MB231 human breast cancer cells.

Nanomedicine (London, England)·2021
Same journal

Mumps resurgence despite MMR: Limitations of current vaccines and the need for new strategies.

Human vaccines & immunotherapeutics·2026
Same journal

The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.

Human vaccines & immunotherapeutics·2026
Same journal

Correction.

Human vaccines & immunotherapeutics·2026
Same journal

Vaccination practice and safety in children with special health care needs: A retrospective study of 1278 children.

Human vaccines & immunotherapeutics·2026
Same journal

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.

Human vaccines & immunotherapeutics·2026
Same journal

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.

Human vaccines & immunotherapeutics·2026
See all related articles

Human papillomavirus (HPV) vaccines offer protection against HPV-associated cancers. Research explores next-generation vaccines using alternative antigens and expression systems to improve cost-effectiveness and global accessibility.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Human papillomavirus (HPV) is the primary cause of various malignancies.
  • Current HPV vaccines are prophylactic, L1-based virus-like particle vaccines, proven safe and effective.
  • Limitations include cost, limited HPV type coverage, and multi-dose schedules hindering global use.

Purpose of the Study:

  • To review current HPV vaccine limitations.
  • To explore novel approaches for next-generation HPV vaccines.
  • To discuss alternative antigens, expression systems, and therapeutic strategies.

Main Methods:

  • Review of existing HPV vaccine technology and clinical trial data.
  • Analysis of alternative antigen strategies (L1, L2) and expression systems (Pichia, measles vector).
Keywords:
HPVL1L2alternate expression systems and affordableprophylactic vaccinestherapeutic vaccinesvirus like particles

Related Experiment Videos

  • Evaluation of preclinical immunogenicity data for novel vaccine candidates.

    • Main Results:

    • Current vaccines demonstrate high safety and efficacy but face accessibility challenges.
    • Alternative expression systems and antigens show promise for improved vaccines.
    • Preclinical studies indicate potential for next-generation prophylactic HPV vaccines.

    Conclusions:

    • Addressing limitations of current HPV vaccines is crucial for global health.
    • Novel vaccine development strategies are essential for broader protection and accessibility.
    • Ongoing research into alternative antigens, expression systems, and therapeutic approaches holds significant promise.